Prevalence and clinical profile of patients with resistant hypertension
Abstract
Objective: To find prevalence and clinical profile of patients with resistant hypertension.
Methods: In a Prospective Observational Study, 100 Hypertensive patients were evaluated in Hypertension OPD, Medical OPD, and Medical Wards. Hypertensive Patient on more than 3 drugs with uncontrolled BP were included for this study. Patients were subjected to Clinical examination, Laboratory investigations and Ultrasound. BP is recorded in all 4 limbs with appropriate cuff size, Patients drug history (Both antihypertensive and other medications for concomitant illness will be enquired), Physical activity and Drug compliance were enquired.
Result: Among the 100 patients studied, 18% patients were found to have Resistant hypertension. Of this, 5 patients were in incorrect drug combination, 7 patients were not drug compliant, 12 patients had Uncontrolled Diabetes, 15 patients had Dyslipidemia, 6 patients had Medical Renal disease, 2 patients had Fatty Liver, 1 patient had Contracted Kidney and 1 patient had Aortailiac Thrombosis.
Conclusion: Incorrect Drug prescription, non-adherence to drugs and metabolic factors played a major role in resistant hypertension in the present study group.
Downloads
References
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6):1403-1419. doi: https://doi.org/10.1161/HYPERTENSIONAHA.108.189141. Epub 2008 Apr 7.
Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005; 18(11):1422-1428. doi: https://doi.org/10.1016/j.amjhyper.2005.05.014.
Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-1080. doi: https://doi.org/10.1161/HYPERTENSIONAHA.111.170308. Epub 2011 Apr 18.
Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011; 124(9):1046-1058. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.030189. Epub 2011 Aug 8.
Lotufo PA1, Pereira AC, Vasconcellos PS, Santos IS, Mill JG, Bensenor IM. Resistant hypertension: riskfactors, subclinical atherosclerosis, and comorbidities among adults-the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). 2015;17(1):74-80. doi: https://doi.org/10.1111/jch.12433. Epub 2014 Oct 23.
Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073-2082. doi: https://dx.doi.org/10.1001/jama.289.16.2073.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117(25):e510-e526. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.189141.
Barochiner J, Alfie J, Aparicio LS, Cuffaro PE, Rada MA, Morales MS, et al. Prevalence and clinical profile of resistant hypertension among treated hypertensive subjects. Clin Exp Hypertens. 2013; 35(6):412-417. doi: https://doi.org/10.3109/10641963.2012.739236. Epub 2012 Nov 13.
Saleem F, Hassali AA, Shafie AA. Hypertension in Pakistan: time to take some serious action. Br J Gen Pract. 2010; 60(575):449-450. doi: https://doi.org/10.3399/bjgp10X502182.
Leenen FH, Dumais J, McInnis NH, Turton P, Stratychuk L, Nemeth K, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ. 2008; 178(11):1441-1449. doi: https://doi.org/10.1503/cmaj.071340.
Kumara WA, Perera T, Dissanayake M, Ranasinghe P, Constantine GR. Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country. BMC Res Notes. 2013;6:373. doi: https://doi.org/10.1186/1756-0500-6-373.
Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13):1635-1642. doi: https://doi.org/10.1161/CIRCULATIONAHA.111.068064. Epub 2012 Feb 29.
Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099–1107. doi: https://doi.org/10.1016/j.mayocp.2013.06.017.
Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertens. 2002; 40(5) :604-608; discussion 601-3. doi: https://doi.org/10.1161/01.HYP.0000035856.77718.DA.
Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertens. 2005;46(3):500-507. Epub 2005 Aug 15. doi: https://doi.org/10.1161/01.HYP.0000177437.07240.70.
Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987; 107(5):628-635. doi: https://dx.doi.org/10.7326/0003-4819-107-5-628.
Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertens. 2000; 36(3):461-465. doi: https://doi.org/10.1161/01.HYP.36.3.461.
Solini A, Zoppini G, Orsi E, Fondelli C, Trevisan R, Vedovato M, et al. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. J Hypertens. 2014; 32(12):2401-2410; discussion 2410. doi: https://dx.doi.org/10.1097/HJH.0000000000000350.
V Fonseca. Management of Patients with Diabetes and Resistant Hypertension, 2016.
Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu LL, Hasstedt SJ, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA. 1988;259(24):3579-3586. doi: https://dx.doi.org/10.1001/jama.1988.03720240041032.
Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. The San Antonio Heart Study. Arch Intern Med. 1996;156(17):1994-2001. doi: https://dx.doi.org/10.1001/archinte.1996.00440160106013.
Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986;80(2A):33-39. doi: https://doi.org/10.1016/0002-9343(86)90158-0.
Castelli WP, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986; 80 (2A):23-32. doi: https://doi.org/10.1016/0002-9343(86)90157-9.
Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000; 35 (4): 549-555. doi: https://dx.doi.org/10.1097/00005344-200004000-00006.
Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A, Party BH. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. American Heart J. 2004;148(2): 285-292. doi: https://doi.org/10.1016/j.ahj.2004.02.003.
OAI - Open Archives Initiative
